Fig. 2

Findings from cost-effectiveness studies. Notes: ⁺ Study reports results in two subgroups: infants born at < 29 weeks ($19,307) vs. born 29–32 weeks (22,863); ⁺⁺ Study reports results in four subgroups: those without BPD and with siblings ($10,456), those with BPD and with siblings ($16,837), those with BPD and without siblings ($34,088), and those without BPD and without siblings ($71,226). Currency is reported in 2020 USD. Abbreviations: BPD, bronchopulmonary dysplasia; DALY, disability-adjusted life year; GDP, gross domestic product; ICER, incremental cost-effectiveness ratio; LIC, low-income country; LMIC, low- and middle-income countries; mAb, Long-acting monoclonal antibody; MI, maternal immunisation; NR, not reported; PI, paediatric immunisation; PVZ, pavilizumab; QALY, quality-adjusted life year; UMIC, upper-middle-income country; USD, United States dollars